Psychiatry AtlasMedication guide · United States

Supervised nasal-spray medicine for selected adult depression

Esketamine (Spravato)

Generic name
esketamine (as esketamine hydrochloride)
Brand names
Spravato
Medication class
Supervised nasal-spray medicine for selected adult depression
Forms covered
Spravato nasal spray

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

FDA Boxed Warning

Spravato nasal spray.

Spravato can cause sedation, dissociation and respiratory depression and has risks of abuse and misuse. Treatment requires a certified REMS setting and at least two hours of monitoring. Antidepressants can increase suicidal thoughts and behaviors in children and young adults; monitor all patients for worsening symptoms. Spravato is not approved for children.

Spravato is a supervised esketamine nasal spray for specific adult depression indications. Learn about eligibility, dosing phases, monitoring, and important safety limits.

What to expect: Some people improve quickly, but response is not guaranteed.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Treatment-resistant depression — Adults. May be used as monotherapy or with an oral antidepressant under the current US label.Spravato nasal spray.
  • Depressive symptoms in MDD with acute suicidal ideation or behavior — Adults. Requires an oral antidepressant. Suicide prevention or reduction of suicidal thoughts or behavior has not been demonstrated; hospitalization may still be needed.Spravato nasal spray.

Read more: Major Depression.

What should I expect?

Some people improve quickly, but response is not guaranteed. For treatment-resistant depression, the team assesses benefit after the four-week starting phase before deciding on continued treatment.

Feeling detached, dizzy or sleepy during a visit is an adverse effect, not proof that depression is improving. Follow-up also reviews function, safety and whether the visit schedule is worthwhile.

How do I take it safely?

Use Spravato only under direct supervision in a REMS-certified healthcare setting. Each visit includes at least two hours of monitoring, with breathing assessment and pulse oximetry, and a clinical stability check before discharge.

Do not eat for at least two hours or drink for at least 30 minutes before treatment. If prescribed nasal steroids or decongestants are needed that day, use them at least one hour beforehand as directed. Arrange transport home; no driving or hazardous activities until the next day after restful sleep.

Blood pressure is checked before treatment and around 40 minutes afterward. Aneurysmal vascular disease, arteriovenous malformation, previous brain hemorrhage and allergy to esketamine or ketamine are contraindications. Other heart or brain-vessel disease needs careful assessment.

Review alcohol, opioids, benzodiazepines and other sedatives, stimulants and MAOIs. Pregnancy and breastfeeding are not recommended during treatment; severe liver impairment is another reason use is not recommended. Report urinary symptoms and worsening mood.

Contact the service about missed visits or stopping. The treatment-resistant depression and acute suicidal-ideation indications have different continuation rules; the latter requires an oral antidepressant and reassessment after four weeks. Spravato has not been shown to prevent suicide and does not replace needed hospitalization.

A history of psychosis or substance-use disorder needs careful assessment and monitoring.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Dissociation, dizziness, nausea, vomiting, sedation, reduced sensation and transient blood-pressure increases.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • The boxed warning covers sedation, dissociation, breathing suppression, abuse or misuse, and suicidal thoughts or behavior. Every dose requires supervised monitoring, including breathing and oxygen levels, for at least two hours.
  • Tell staff immediately about breathing difficulty, inability to stay awake, chest pain, sudden severe headache, seizure or new weakness; these need emergency assessment. Report urinary pain, frequency or blood in urine promptly.
  • Contact the prescriber promptly for new suicidal thoughts, worsening depression or unusual behavior. Use emergency care if there is immediate danger or the person cannot stay safe. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior and does not replace needed hospitalization.

What else should I know to stay safe?

  • Do not use with aneurysmal vascular disease, arteriovenous malformation, previous brain hemorrhage, or allergy to esketamine, ketamine or ingredients. Other cardiovascular or brain-vessel disease, psychosis and substance-use history need assessment; severe liver impairment is a reason use is not recommended.
  • Blood pressure must be assessed before and after treatment. Review alcohol, opioids, benzodiazepines, other sedatives, stimulants and MAOIs. Pregnancy and breastfeeding are not recommended during treatment.
  • Arrange transport home and do not drive or undertake hazardous activities until the following day after restful sleep. Treatment continuation is indication-specific: the acute suicidal-ideation indication requires an oral antidepressant and reassessment after four weeks; its longer use has not been systematically evaluated.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Two hours is the minimum observation period, not a guaranteed discharge time. Staff must also confirm that you are clinically stable.
  • Spravato has not been shown to prevent suicide. Hospital care may still be needed even when depressive symptoms improve after a visit.
  • This supervised nasal spray is a different product from compounded ketamine. Their evidence and treatment requirements cannot be transferred automatically.

How does it work?

Esketamine changes how nerve cells communicate using glutamate, a chemical messenger. It reduces activity through NMDA receptors, one type of protein that responds to glutamate. This action is established, but the changes that lead to an antidepressant effect in people are not fully understood.

Explore medication science

How was this medicine developed?

Spravato first received FDA approval in 2019 for adult treatment-resistant depression. Later labeling expanded its uses and now permits treatment-resistant depression treatment alone or with an oral antidepressant; the acute suicidal-ideation indication still requires an oral antidepressant.

How do I say the name?

Esketamine: es-KET-a-meen. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Spravato: current US prescribing information (revised March 2026)
  2. Esketamine Nasal Spray: MedlinePlus Drug Information
  3. Advancing Health Through Innovation: New Drug Therapy Approvals 2019
  4. Spravato FDA Medication Guide
  5. Drugs@FDA: FDA-Approved Drugs
  6. Spravato: Package Insert / Prescribing Information / MOA
  7. FDA June 2026 warning letter: ketamine approval status and unapproved products
  8. Ketamine and neural changes: animal research and its limits
  9. Depression: treatment and brain stimulation options
  10. Ketalar: current US prescribing information (revised March 2026)
  11. Ketamine versus ECT for nonpsychotic treatment-resistant major depression (randomised trial, 2023)
  12. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters..

  13. Ketamine Lifts Depression via a Byproduct of its Metabolism — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Mouse experiments involving hydroxynorketamine and AMPA receptors; confirmation in humans explicitly pending..

  14. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Abstract: channel-opening experiments and conclusions..

  15. Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Summary; Introduction; S-(+)-ketamine closes the GluN1a-2B-2D NMDAR channel gate and blocks the pore..

  16. ISMP List of Confused Drug Names
  17. Spravato full prescribing information — FDA prescribing information
  18. NIMH: Understanding psychosis
  19. Frequently Asked Questions about Labeling for Prescription Medicines | FDA

Giving medicine safely to children: family guide (PDF, 3 pages)

Ketamine vs Esketamine

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top